These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma.
    Author: Cuttner J, Wasserman LR, Martz G, Sonntag RW, Kyle RA, Silver RT, Spurr C, Harley JB, Wiernik PM, Cornwell GG, Falkson G, Glidewell O, Holland JF.
    Journal: Med Pediatr Oncol; 1975; 1(3):207-16. PubMed ID: 1232529.
    Abstract:
    A study was designed to evaluate the effectiveness of prednisone therapy in poor-risk patients with multiple myeloma. Patients were treated with melphalan alone or in combination with prednisone at doses of either 0.6 mg/kg or 0.3 mg/kg. The group of patients receiving melphalan and prednisone 0.6 mg/kg had significantly improved responses in hemoglobin, lowering of the M-protein concentration, and reduction of azotemia. Significant benefits attributable to prednisone were not demonstrated in the group receiving 0.3 mg/kg. Good responses have been shown to produce improved survival. The combination of melphalan and prednisone is effective in producing good responses, but the dose of steroids is important. A dose of prednisone of 0.6 mg/kg in gradually decreasing doses has been found to be effective in production of good responses, especially in the uremic patient.
    [Abstract] [Full Text] [Related] [New Search]